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Prognostic Factors of Tuberculous Meningitis in Adults: 
A 6-Year Retrospective Study at a Tertiary Hospital in 
Northern Taiwan
Po-Chang Hsu, Chien-Chang Yang, Jung-Jr Ye, Po-Yen Huang, Ping-Cherng Chiang, Ming-Hsun Lee*
Division of Infectious Diseases, Department of Internal Medicine, Chang Gung Memorial Hospital, 
 Chang Gung University College of Medicine, Taoyuan, Taiwan.
BACKGROUND/PURPOSE: To investigate the clinical features, laboratory test results, imaging data, 
and prognostic predictors of tuberculous meningitis (TBM) in adults.
METHODS: We retrospectively reviewed 108 adult patients with a diagnosis of TBM over a 6-year period. 
Patients were divided into “definite” and “probable” groups, depending on the diagnosis made by (1) pos-
itive culture, or polymerase chain reaction, of Mycobacterium tuberculosis (TB) from the cerebrospinal fluid 
(CSF); or (2) the isolation of TB elsewhere, or chest radiography consistent with active pulmonary TB, or 
imaging studies of the brain consistent with TBM, or clinical improvement on treatment. These two 
groups were compared for their clinical features, images, laboratory test results, and 9-month mortality 
rates to identify prognostic predictors.
RESULTS: Compared with the “probable” group (n = 62), the “definite” group (n = 46) had a higher mor-
tality rate (50.0% vs. 30.6%, p = 0.041) and more consciousness disturbance (78.3% vs. 51.6%, p = 0.005), 
hydrocephalus (63.4% vs. 40.7%, p = 0.029) and isolation of TB from extra-CSF specimens (41.3% vs. 22.6%, 
p = 0.037). Old age (p = 0.002), consciousness change (p = 0.032), and hydrocephalus (p = 0.047) were poor 
prognostic indicators in the “definite” group as assessed by univariate analysis. Severity of TBM at admis-
sion and delayed anti-TB therapy resulted in a poor prognosis for all patients. Multiple logistic regression 
analysis showed that old age and hydrocephalus were independent factors for mortality. Adjunctive ster-
oid therapy over 2 weeks improved survival in both the “definite” (p = 0.002) and “probable” (p = 0.035) 
groups, but more than 4 weeks of use had no significant effect on mortality. Steroid treatment, therefore, 
may improve the outcome of patients with TBM.
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Introduction
Mycobacterium tuberculosis remains a global epidemic, espe-
cially in Asia. In 2006, 9.2 million new cases and 1.7 mil-
lion deaths from tuberculosis (TB) occurred, of which 0.7 
million cases and 0.2 million deaths were in HIV-positive 
people.1 M. tuberculosis infection is still an important 
public health issue worldwide. Tuberculous meningitis 
(TBM) is a major cause of this serious illness in many 
parts of the world, especially in developing countries.2 
The mortality rate for TBM is around 20–41%.2–4 Many 
prognostic factors for TBM have been reported, including 
age, the stage of the disease, level of consciousness, pres-
ence of extra-central nervous system (CNS) TB, iso lation of 
M. tuberculosis from cerebrospinal fluid (CSF), biochemi-
cal studies of CSF, hydrocephalus, and in farction.5–7 Even 
so, early diagnosis and treatment of the disease is the most 
important factor affecting complications and mortality 
rates.6,8,9 However, it is still difficult, using the current pa-
rameters, to make an early and precise diagnosis on the 
basis of laboratory results.10
TBM still causes death, or severe neurologic deficits, 
despite the advent of newer antituberculous (anti-TB) 
agents and imaging techniques. Recently, some studies 
have reported that, adjunctive steroids might be of benefit 
to patients with TBM.11,12
Hydrocephalus is a frequent complication of TBM 
and, as yet, the best way to manage this has still to be 
found. The emergence of drug-resistant strains has in-
creased in many parts of the world and this disease 
presents a therapeutic challenge.13 Thus, to identify 
prognostic predictors for TBM, we conducted a retro-
spective study at a tertiary teaching hospital over a 6-year 
period in which we evaluated clinical outcomes, labora-
tory data, neuroimaging results, and therapeutic factors 
associated with mortality in patients with a diagnosis 
of TBM.
Methods
Patients and study design
Data obtained from patients (aged ≥ 16 years) admitted 
to the Chang Gung Memorial Hospital-Linkou Medical 
Center between January 2000 and September 2006 with a 
diagnosis of TBM was analyzed retrospectively. The pa-
tients’ medical records were reviewed, and the following 
information was collected: demographic characteristics, 
underlying diseases, clinical features, laboratory data, 
bacteriology, image studies, use of steroids, mannitol and 
anti-TB agents, surgical interventions or drainage, and 
clinical outcome. Most patients had CSF taken on ad-
mission, and the following tests performed: total cell 
count, glucose, protein and lactate levels, polymerase 
chain reaction for TB (TB-PCR), and mycobacterial smears 
and cultures. We also collected follow-up CSF data, if 
available. Chest radiography was performed on all pa-
tients on admission, and brain computed tomography 
(CT) scans or magnetic resonance imaging (MRI) studies 
were done for most patients after admission. Findings 
consistent with TBM in the brain CT or MRI scans were as 
follows: exudates in the basal cisterns, hydrocephalus, 
gyral enhancement, tuberculoma, vasculitis, and abscess 
or infarcts.
The diagnosis of TBM was based on clinical features, 
routine CSF screens, biochemistry, microbiologic cul-
tures, and brain imaging results.14 Clinical features in-
cluded fever for more than 7 days, headache, or neck 
stiffness. Patients were classified into one of two groups; 
“definite” or “probable”, to assess differences in mortality 
and clinical severity. “Definite” TBM was defined as the 
isolation of M. tuberculosis from one or more CSF cul-
tures, and/or positive TB-PCR. “Probable” TBM was de-
fined as the presence of CSF findings compatible with 
TBM, i.e., CSF leukocyte count > 10/μL (with a predomi-
nance of lymphocytes), protein > 40 mg/dL, low CSF/serum 
CONCLUSION: Old age, advanced stage of TBM at admission, hydrocephalus, and positive TB culture 
or polymerase chain reaction of CSF are factors associated with a poor prognosis for TBM. Early diagnosis 
and treatment, including short term steroid use, are mandatory for clinical care of adult patients 
with TBM.
KEYWORDS: hydrocephalus, prognostic factors, steroid, tuberculous meningitis
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glucose ratios (< 0.6), or < 60 mg/dL, plus one or more of 
the following criteria: (1) isolation of M. tuberculosis from 
specimens other than the CSF, or findings of active pulmo-
nary TB on chest radiography; (2) radiological findings 
on cranial CT or MRI consistent with TBM; (3) a history 
of TB infection; and (4) clinical improvement after anti-
TB treatment.2,9 Patients were excluded from the statistics 
if they had any evidence of CNS malignancy (n = 3), or 
were lost to follow-up (n = 9) during, or after, the period 
of anti-TB treatment. The duration of loss of follow-up 
was 6 days to 5 months (mean, 3.7 months).
The severity of TBM at the time of admission was as-
sessed using the British Medical Research Council TBM 
grades.15 Grade I is defined as a Glasgow coma score 
(GCS) of 15 without focal neurological signs; grade II 
is defined as a GCS of 15 with neurological deficit, or a 
GCS of 11–14; and grade III is defined as a GCS of  ≤ 10.
Treatment
Patients received a minimum of two bactericidal anti-TB 
agents such as isoniazid (INH) 300 mg/day, rifampicin 
(RIF) 450–600 mg/day, or pyrazinamide 1000–1500 mg/
day, either with or without ethambutol 800–1200 mg/
day, for at least 6 months—unless the patient died. Other 
anti-TB agents such as ciprofloxacin 1 g/day, levofloxacin 
500 mg/day, or streptomycin 15 mg/kg/day, were used 
tem porarily in patients who experienced drug toxicity. 
The time between the onset of presenting clinical features 
and the start of anti-TB therapy was recorded. Adjunctive 
steroid therapy was defined as the use of prednisolone ≥ 
20 mg/day for at least 7 consecutive days, and the treat-
ment duration was categorized as over 7 days, 14 days, 21 
days, and 28 days. Hydrocephalus was treated with ster-
oids, mannitol, or surgical intervention. The outcome 
was assessed in terms of survival after 9 months from 
entry (9-month mortality).
Statistical analysis
Continuous variables were expressed as mean ± standard 
deviation, and categorical variables as a proportion of the 
total number of patients. Univariate analysis was con-
ducted using either a χ2 test, or Fisher’s exact test for cat-
egorical variables, and Student’s t test, or Mann-Whitney 
U test, for continuous variables, as indicated. The relation-
ship between mortality and disease stage was evaluated 
using logistic regression analysis. To eliminate confound-
ing factors in predicting the risk for mortality, variables 
with p values ≤ 0.1 by univariate analysis were entered into 
a multivariate logistic regression model for further as-
sessment. All statistical calculations were analyzed using 
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA). Results 
were expressed as adjusted odds ratios, and correspond-
ing 95% confidential interval (CI). A p value of < 0.05 was 
regarded as significant.
Results
A total of 108 patients were included in this study. Their 
demographic and clinical features, along with laboratory 
data are summarized in Table 1. Of the 108 patients, 71 
(65.7%) were male. The mean age of the patients was 54.9 ± 
18.6 years (range, 19–87 years). The common presenting 
symptoms and signs were as follows: fever (81.5%), con-
sciousness disturbance (63.0%), headache (60.2%), neck 
stiffness (54.6%), vomiting (20.3%), seizure (13.9%), unsta-
ble gait (7.4%), double vision (5.6%), photophobia (2.7%), 
urinary incontinence (2.7%), hemiplegia (1.8%), and deaf-
ness (0.9%). On admission, 24 patients (22.2%) were classi-
fied as stage I, 56 (51.9%) as stage II, and 28 (25.9%) as 
stage III. Isolation of M. tuberculosis from specimens other 
than the CSF was positive in 33 patients. These included 
sputum or bronchial alveolar lavage samples (26 patients), 
muscle abscess (1 patient), urine (1 patient), and simulta-
neous multiple sites (5 patients). The simultaneous mul-
tiple sites included sputum and spinal tissue (2 patients); 
sputum and urine (1 patient); sputum and ascites (1 pa-
tient); sputum, lymph node, pericardium and spinal 
tissue (1 patient).
Of the 108 patients, one had a positive CSF smear for 
acid fast stain, with both positive culture and PCR. PCR 
for the specific detection of M. tuberculosis was carried out 
in 49 cases, 15 (30.6%) of which were positive. Forty-two 
patients (38.9%) had M. tuberculosis isolated from CSF 
specimens, and six of the isolates (14.6%) were resistant 
strains; two INH-resistant strains, one RIF-resistant 
strain, one pyrazinamide-resistant strain, one streptomy-
cin-resistant strain, and one multiple-drug (INH, RIF and 
ethambutol) resistant strain.
Routine CSF results were as follows: leukocyte count, 
220.4 ± 312.7/μL; protein levels, 316.2 ± 434.6 mg/dL; 
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glucose levels, 44.8 ± 31.1 mg/dL; and lactate levels, 53.0 ± 
23.3 mg/dL.
Ninety-five patients had brain CT or MRI scans dur-
ing their hospital stay. Twenty-four patients had negative 
findings. Positive image findings were as follows: hydro-
cephalus (48 patients, 50.5%), meningitis signs (29 pa-
tients, 30.5%; with leptomeningeal enhancement in 12 
patients, basal cisterns enhancement in 9 patients, fronto-
temporal enhancement in 3 patients, granulomatous en-
hancement in 1 patient, tentorium and sulci fissure 
enhancement in 1 patient and radiologist-suspected 
meningitis in 3 patients), infarction (22 patients, 23.2%), 
abscess (4 patients, 4.2%), tuberculoma (4 patients, 4.2%), 
and vasculitis (2 patients, 2.1%). Forty-two patients (38.9%) 
died within 9 months. The mean time of death was 63.8 ± 62.4 
days (range, 5–232 days), with 75% dying within 90 days.
Forty-six patients were assigned to the “definite” 
group. Twenty-three patients (50%) in the “definite” 
group, and 19 patients (30.6%) in the “probable” group, 
died. The “definite” group had a higher mortality rate 
(p = 0.041), and patients had more advanced disease on ad-
mission compared with the “probable” group (p = 0.015). 
However, the mean number of days between admission 
and death was not significantly different between the two 
Table 1. Demographic and clinical characteristics in patients with tuberculous meningitisa
Characteristics
 “Definite”  “Probable”  Total patients 
Univariate pb patients (n = 46) patients (n = 62) (n = 108)
Age (yr) 56.7 ± 19.2 53.7 ± 18.2 54.9 ± 18.6 0.395
Gender, male 27 (58.7) 43 (69.4) 71 (65.7) 0.251
Presentations    
  Fever (> 38ºC) 37 (80.4) 51 (82.3) 88 (81.5) 0.809
  Conscious disturbance 36 (78.3) 32 (51.6) 68 (63.0) 0.005
  Headache 25 (54.3) 40 (64.5) 65 (60.2) 0.214
  Neck stiffness 21 (45.7) 38 (61.3) 59 (54.6) 0.106
Tuberculosis other than CNS 19 (41.3) 14 (22.6) 33 (30.6) 0.037
Stage of TBM at admission    
  Stage I 5 (10.9) 19 (30.6) 24 (22.2) 0.015
  Stage II 24 (52.2) 32 (51.6) 56 (51.9) 
  Stage III 17 (37.0) 11 (17.7) 28 (25.9) 
CSF routine    
  WBC (/μL) 221.8 ± 306.5 219.5 ± 319.5 220.4 ± 312.7 0.693
  Protein (mg/dL) 346.3 ± 548.1 293.7 ± 334.2 316.2 ± 434.6 0.250
  Glucose (mg/dL) 42.4 ± 34.4 46.6 ± 28.8 44.8 ± 31.1 0.092
  Lactate (mg/dL) 62.2 ± 23.7 46.9 ± 21.1 53.0 ± 23.3 0.002
Imagec
  Hydrocephalus 26 (63.4) 22 (40.7) 48 (50.5) 0.029
  Meningitis signd 11 (26.8) 18 (33.3) 29 (30.5) 0.495
  Infarction  9 (22.0) 13 (24.1) 22 (23.2) 0.808
Mortality 23 (50.0) 19 (30.6) 42 (38.9) 0.041
Duration between admission 61.1 ± 70.9 (5–232) 67.03 ± 52.1 (5–205) 63.8 ± 62.4 (5–232) 0.097
and death (d)
aData presented as n (%), mean ± standard deviation or mean ± standard deviation (range); bcomparison between “definite” group and “prob-
able” group; c95 patients had imaging data, of them 41 were in “definite”, 54 in “probable”; dexudates in basal cisterns, hydrocephalus, gyral 
enhancement, tuberculoma, vasculitis, abscess, or infarcts. CNS = Central nervous system; TBM = tuberculous meningitis; CSF = cerebrospinal 
fluid; WBC = white blood cells.
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groups (61.1 ± 70.9 vs. 67.03 ± 52.1, p = 0.097). Moreover, 
consciousness disturbance, hydrocephalus, and a higher 
rate of extra-CNS TB were more common in the “definite” 
group, 78.3% vs. 51.6%, (p = 0.005); 63.4% vs. 40.7%, 
(p = 0.029); and 41.3% vs. 22.6%, (p = 0.037), respectively.
In the “definite” group, univariate analysis revealed 
that both old age (p = 0.002) and consciousness distur-
bance (p = 0.032) were associated with a higher mortality 
(Table 2). As for the image findings, hydrocephalus was 
the most frequent finding and was obviously correlated 
Table 2. Prognostic factors in patients with tuberculous meningitisa
Variables
 “Definite” patients (n = 46) “Probable” patients (n = 62) Total patients (n = 108)
 Deceased Survived Univariate Deceased  Survived Univariate Deceased Survived Univariate
 (n = 23) (n = 23) p (n = 19) (n = 43) p (n = 42) (n = 66) p
Mean age (yr)  64.6 48.6 0.002  66.6  48.0 < 0.001  65.5  48.2 < 0.001
Age > 60  15 (65.2)  7 (30.4) 0.018 13 (68.4) 12 (27.9)   0.003 28 (66.7) 19 (28.8) < 0.001
Gender, male  16 (69.6) 11 (47.8) 0.134 10 (52.6) 33 (76.7)   0.058 26 (61.9) 44 (66.7)   0.613
TB other than CNS  12 (52.2)  7 (30.4) 0.134  5 (26.3)  9 (20.9)   0.744 17 (40.5) 16 (24.2)   0.074
Presentations
  Fever 20 (87.0) 17 (73.9) 0.265 14 (22.6) 37 (59.7)   0.240 34 (31.5) 54 (50.0)   0.910
  Headache 11 (47.8) 14 (60.9) 0.375 11 (57.9) 30 (69.8)   0.362 22 (52.4) 44 (66.7)   0.138
  Conscious change 21 (91.3) 15 (65.2) 0.032 12 (63.2) 20 (46.5)   0.227 33 (78.6) 35 (53.0)   0.007
  Neck stiffness 10 (43.5) 11 (47.8) 0.767  9 (47.4) 29 (67.4)   0.135 19 (45.2) 40 (60.6)   0.118
CSF routine
  WBC (/μL)  140.0 116.5 0.544  49.0 145.0   0.002  97.0 135.0   0.084
  Protein (mg/dL) 259.0 211.6 0.680 187.0 200.2   0.434 237.7 208.3   0.312
  Glucose (mg/dL)   33.0 30.0 0.697  44.5  40.0   0.591  41.5  36.5   0.764
  Lactate (mg/dL)  60.0 59.6 0.457  53.7  40.9   0.449  58.1  54.0   0.110
Stage of TBM at
admission
  Stage I 2 (8.7)  3 (13.0) 0.101  5 (26.3) 14 (32.6)   0.165  7 (16.7) 17 (25.8)   0.006
  Stage II  9 (39.1) 15 (65.2)   8 (42.1) 24 (55.8)  17 (40.5) 39 (59.1) 
  Stage III 12 (52.2)  5 (21.7)   6 (31.6)  5 (11.6)  18 (42.9) 10 (15.2) 
Timing of starting  15.9 12.6 0.176  20.6  12.5   0.127  18.2 12.6   0.044
anti-TBb (d)
Steroid
  > 1week  8 (34.8) 14 (60.9) 0.077  4 (21.1) 20 (46.5)   0.058 12 (28.6) 34 (51.5)   0.019
  > 2 weeks 1 (4.3) 10 (43.5) 0.002  2 (10.5) 17 (39.5)    0.035 3 (7.1) 27 (40.9) < 0.001
  > 3 weeks 1 (4.3)  9 (39.1) 0.004 1 (5.3)  9 (20.9)   0.155 2 (4.8) 18 (27.3)   0.003
  > 4 weeks 1 (4.3)  4 (17.4) 0.346 1 (5.3) 4 (9.3)   1.000 2 (4.8)  8 (12.1)   0.310
Mannitol  8 (34.8)  8 (34.8) 1.000  5 (26.3) 14 (32.6)   0.623 13 (31.0) 22 (33.3)   0.797
Image (n = 22) (n = 19)  (n = 18) (n = 36)  (n = 40) (n = 55)
  Hydrocephalus 17 (77.3)  9 (47.4) 0.047 13 (72.2)   9 (25.07)   0.001 30 (75.0) 18 (32.7) < 0.001
  Infarction  7 (31.8)  2 (10.5) 0.140  4 (22.2)  9 (25.0)   0.882 11 (27.5) 11 (20.0)   0.392
  Meningitis sign  4 (18.2)  7 (36.8) 0.179  7 (38.9) 11 (30.6)   0.540 11 (27.5) 18 (32.7)   0.586
aData presented as n (%) or mean; bduration between the onset of presenting clinical features and the start of antituberculous therapy. 
TB = Tuberculosis; CNS = central nervous system; CSF = cerebrospinal fluid; WBC = white blood cells; TBM = tuberculous meningitis.
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with mortality (p = 0.047), and adjunctive steroid therapy 
over 2 or 3 weeks was associated with a significantly re-
duced risk of death. The deceased patients had experi-
enced greater delays in the administration of anti-TB 
agents than those that survived (15.9 ± 9.1 vs. 12.6 ± 7.3 
days), but this difference was not significant (p = 0.176). 
Age and hydrocephalus were also significantly associated 
with higher mortality in the “probable” group, p < 0.001 
and p = 0.001, respectively, and adjunctive steroid use 
over 2 weeks significantly reduced the mortality rate 
(p = 0.035). Overall, the CSF white cell count was lower in 
those patients that survived than in those that did not 
(p = 0.002).
The potential risk factors for mortality in all patients 
are listed in Table 2. Statistically significant factors were: 
age over 60 years (p < 0.001), consciousness disturbance 
(p = 0.007), and hydrocephalus (p < 0.001). The staging 
of TBM at admission was associated with increased mor-
tality in all patients (p = 0.006). Logistic regression analy-
sis showed that, for all patients, there was no statistical 
difference in mortality between TBM stage I and stage II 
(p = 0.915; 95% CI = 0.371–3.020), but patients with TBM 
stage III had a higher mortality rates compared with those 
with TBM stage I (p = 0.014; 95% CI = 1.355–14.10). In this 
case, the deceased patients had experienced significant 
delays in the administration of anti-TB agents compared 
with those that survived (18.2 ± 12.6 vs. 12.6 ± 6.3 days; 
p = 0.044). Those patients treated with steroids over one, 
2 or 3 weeks had a lower mortality rate (p = 0.019, p < 0.001, 
and p = 0.003, respectively), but this was not statistically 
significant in patients treated over 4 weeks (p = 0.310). 
Variables used in the multivariate logistic regression in-
cluded age, CSF white cell counts, isolation of M. tubercu-
losis or positive TB-PCR in CSF, stage of TBM, the timing 
anti-TB therapy administration, steroid treatment over 2 
weeks, extra-CNS TB, and hydrocephalus (Table 3). The 
results show that age (p = 0.041), hydrocephalus (p = 0.016), 
and delays in starting anti-TB therapy and steroids 
(p = 0.001) were independently associated with increased 
mortality. Forty-eight patients had hydrocephalus, and 
steroid treatment improved the outcome in these patients 
by reducing the mortality rate in this group (p < 0.001). 
Ventriculoperitoneal (V-P) shunt/CSF drainage and man-
nitol treatment did not improve the mortality rates 
(p = 0.450 and p = 0.499, respectively).
Discussion
Tuberculosis is an endemic disease in Taiwan, and TBM is 
an important public health issue. The overall 9-month 
mortality rate in this study was 38.9% (42/108), which 
is similar to the mortality rate reported by Roca and 
Tornador.3 The three most common symptoms of our 
TBM patients on admission were fever, consciousness dis-
turbance, and headache. Consciousness disturbance was 
statistically correlated to mortality. We also found that 
old age, which has been shown to correlate with poor out-
comes in previous studies16,17 was also a factor in our 
study. The deaths in this study tended to be among the 
elderly (65.5 vs. 48.2 years, p < 0.001), supporting the rela-
tionship between age and mortality in patients with TBM. 
The staging of TBM depends on the neurological signs 
and state of consciousness on admission. Previous studies 
indicate a correlation between the severity of TBM and 
poor out come,2,4,17 and this is confirmed by our study 
(p = 0.006). Stage III disease resulted in a higher mortality 
rate than stage I, but there was no significant difference 
Table 3. Multivariate logistic regression model showing the 
parameters for the mortality of tuberculous meningitis
Risk factor Odds ratio (95% CI) p
Age  1.046 (1.002–1.091) 0.041
Isolation of TB or 1.153 (0.302–4.406) 0.835
positive TB-PCR in CSF
Tuberculosis other 1.168 (0.246–5.554) 0.845
than CNS
CSF WBC 1.001 (0.999–1.003) 0.547
Conscious change 1.675 (0.207–13.572) 0.629
Stage of TBM  
  II vs. I 0.455 (0.052–3.985) 0.477
  III vs. I 1.945 (0.141–26.912) 0.620
Timing of starting 1.082 (0.996–1.175) 0.063
anti-TBa
Steroid for 2 weeks 0.032 (0.005–0.224) 0.001
Hydrocephalus 4.977 (1.345–18.410) 0.016
aDuration between the onset of presenting clinical features and the 
start of antituberculous therapy. CI = Confidence interval; CNS = 
central nervous system; CSF = cerebrospinal fluid; TB-PCR = tubercu-
losis polymerase chain reaction; WBC = the white blood cell count; 
TBM = tuberculous meningitis.
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between stages I and II. The timing of the start of anti-TB 
therapy was also an important factor that influenced 
the out come.8,9 In this study, we found that deceased pa-
tients in the “definite” group had experienced greater 
delay in receiving treatment compared with those that 
survived. Early anti-TB therapy reduced the mortality rate 
in all patients as assessed by univariate analysis. Hence, 
early diagnosis and treatment are essential to avoid seri-
ous co-morbidity.
Previous studies show that the prognostic factors for 
TBM include CSF glucose levels, protein and lactate 
levels, and the presence of extra-CNS tuberculosis,6,17 
but this was not confirmed by our study (p = 0.764, 
p = 0.312, p = 0.110 and p = 0.074, respectively; Table 2). 
Age, comatose mental status, cranial nerve palsy, stage 
of TBM, delayed or interrupted treatment, and hydroceph-
alus have all been reported to be predictors for mortality 
by logistic regression analysis.6,7 In this study, old age and 
hydrocephalus (identified by the imaging studies) carried 
an increased risk of death. Multivariate logistic regression 
analysis identified adjunctive steroid therapy as a protec-
tive factor, (Table 4).
The increase in the incidence of drug-resistant M. tu-
berculosis strains causes a serious problem worldwide, and 
makes therapy difficult, especially in developing coun-
tries. This study shows that 14.6% (6/41) of culture-proved 
TBM cases were resistant, which is similar to previous 
reports from Taiwan.6,18 Only one patient infected with 
a multiple drug-resistant strain died. There was no signif-
icant correlation between the resistant strains and mor-
tality (p = 0.182), but the result still raises our attention 
to this problem.
Positive M. tuberculosis culture from CSF was associated 
with a poor prognosis,5 and this observation may indicate 
that higher microbe loading and burden led to an in-
creased risk of developing consciousness disturbances, 
hydrocephalus, more serious TBM stages, and subsequent 
mortality in the “definite” group compared with the 
“probable” group. Univariate analysis showed that, in the 
“definite” group, consciousness disturbance and old age 
were correlated with an increased mortality rate. However, 
comparison of the TBM stage did not show any statistical 
differences in mortality (Table 2). However, the small 
number of patients in the “definite” group may make it 
difficult to clarify the relationship between TBM stage 
and mortality.
Brain CT or MRI studies of TBM patients may show 
hydrocephalus, parenchymal enhancement, contrast en-
hancement of basal cisterns, cerebral infarct, focal or 
diffuse brain edema, abscess or tuberculoma;19 and hy-
drocephalus is known to be an important predictor for 
outcome.7 In this study, hydrocephalus was the most 
common finding in the imaging studies and was asso-
ciated with poor outcome. Hence, the management of 
hydrocephalus is an important issue for TBM patients. 
How ever, the indications for the implantation of V-P 
shunts, or CSF drainage, for TBM remain controversial. 
The usefulness of V-P shunts is debatable, although some 
authors suggest that a rapid deterioration of conscious-
ness might be caused by ventricular dilation, and that 
early shunting remains the best option to prevent long-
term neurological sequelae and improve the clinical 
outcome.20,21 Conversely, some studies show that drain-
age does not alter the course of disease, and might even 
result in the added complication of CNS diversion.22 In 
this study, 48 patients had hydrocephalus, which im-
proved after steroid therapy. However, V-P shunts, CSF 
drainage, and mannitol use were not associated with 
improved mortality. Steroid treatment is thought to de-
crease the severity of hydrocephalus, but as most patients 
in our study did not receive subsequent CT/MRI follow-
ups, we cannot evaluate the relationship between steroid 
treatment and hydrocephalus.
This study shows that mortality was reduced in both 
the “definite” and “probable” groups if they received pred-
nisolone ≥ 20 mg/day over a 2-week period. Some studies 
report that steroids modulate acute CSF protein concen-
tration, and reduce interferon-gamma concentrations, 
cell counts and cerebral edema.23,24 We retrospectively 
traced the records of patients who had two or more CSF 
work-ups (n = 66), and found that most patients treated 
Table 4. Management in patients with hydrocephalus
 Deceased Survived Univariate
 (n = 30)  (n = 18) p 
Steroid 9 (30.0) 15 (83.3)  < 0.001
Mannitol 12 (40.0) 9 (50.0) 0.499
Shunting or drainage 7 (23.3) 6 (33.3) 0.450
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with steroids had decreased CSF protein concentrations 
compared with those who did not receive steroids (83.3% vs. 
57.1%; p = 0.030). However, the white cell count, and the 
glucose and lactate levels in CSF showed no statistical cor-
relation with steroid treatment, and it is not clear 
for how long steroids should be used. Some studies sug-
gest giving steroids for at least 7–10 days,11 but some sug-
gest as long as 8 weeks.12 Our data show that the mortality 
rate was reduced when using steroids over 2–4 weeks, and 
was associated with clinical improvement. However, there 
was no significant difference in survival when steroids 
were used for 4 weeks. Perhaps giving steroids for 2–4 
weeks is the optimal for TBM, but there is still room for 
further work in this area, especially as the dosage and 
duration of steroid therapy varied in our study.
In conclusion, old age, consciousness changes, TBM 
stage III, and hydrocephalus suggest a poor prognosis 
for TBM, as does isolation of M. tuberculosis from the CSF, 
or positive CSF TB-PCR. In addition, delay in giving anti-
TB therapy has a significant influence on mortality, and 
early diagnosis and prompt treatment play a key role in 
survival. Steroid therapy improves the survival rate in 
adult TBM, especially in those patients with hydrocepha-
lus. Therefore, adjunctive steroid therapy should be ad-
ministered for at least 2 weeks. However, the optimal dose 
and duration of steroid therapy need to be investigated 
further.
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